RxDoctor Payments Data

Manuel Quinones

Endocrinology, Diabetes & Metabolism · Redondo Beach, CANPI 1861667164

Payments from drug & device makers

$190,764in general payments, 2019–2025

Across 283 payments — averaging $674.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$82K
  • AstraZeneca$61K
  • Johnson & Johnson$47K
  • Boehringer Ingelheim$118
  • Abbott$25
  • Sanofi-aventis U.S. LLC$22
  • plus $14 from 1 others

What the payments were for

  • Consulting fees$1,8801%
  • Speaking & faculty fees$174,31591%
  • Travel & lodging$7,9094%
  • Food & beverage$6,6603%

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk126$81,977
AstraZeneca69$61,384
Johnson & Johnson80$47,224
Boehringer Ingelheim5$118
Abbott1$25
Sanofi-aventis U.S. LLC1$22
Merck1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$190,764 in reported general payments places this provider in the 90th percentile of 952 endocrinology, diabetes & metabolism providers in California.

See all endocrinology, diabetes & metabolism providers in California

Other endocrinology, diabetes & metabolism in Redondo Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →